|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.670 USD | -.--% |
|
-.--% | - |
| 07/10/25 | MannKind Corporation completed the acquisition of scPharmaceuticals Inc.. | CI |
| 07/10/25 | MannKind Completes Acquisition of scPharmaceuticals | MT |
Company Valuation: scPharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 105.5 | 144.5 | 137.3 | 244.2 | 224.8 | 177.1 |
| Change | - | 37.04% | -4.98% | 77.8% | -7.91% | -21.22% |
| Enterprise Value (EV) 1 | 53.87 | 59.64 | 79.68 | 161.9 | 188.1 | 153.2 |
| Change | - | 10.71% | 33.61% | 103.21% | 16.18% | -18.59% |
| P/E | -3.19x | -4.04x | -4.9x | -5.52x | -4.41x | -1.85x |
| PBR | 2.05x | 1.76x | 2.43x | 3.39x | 6.06x | 13.3x |
| PEG | - | 0.2x | 0.2x | -0.2x | -0.46x | -0.1x |
| Capitalization / Revenue | - | - | - | - | 16,541,258x | 4,875,649x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -1.64x | -1.99x | -3.09x | -4.48x | -3.4x | -2.37x |
| EV / EBIT | -1.64x | -1.99x | -3.09x | -4.48x | -3.4x | -2.36x |
| EV / FCF | -2.81x | -3.72x | -4.66x | -8.17x | -4.66x | -3.27x |
| FCF Yield | -35.5% | -26.8% | -21.5% | -12.2% | -21.5% | -30.6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.774 | -1.311 | -1.025 | -1.299 | -1.423 | -1.913 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | 13.59 | 36.33 |
| EBITDA 1 | -32.87 | -29.9 | -25.79 | -36.12 | -55.37 | -64.76 |
| EBIT 1 | -32.9 | -29.93 | -25.82 | -36.16 | -55.4 | -64.78 |
| Net income 1 | -33 | -32.21 | -28.03 | -36.84 | -54.81 | -85.15 |
| Net Debt 1 | -51.59 | -84.89 | -57.64 | -82.25 | -36.72 | -23.98 |
| Reference price 2 | 5.660 | 5.290 | 5.020 | 7.170 | 6.270 | 3.540 |
| Nbr of stocks (in thousands) | 18,634 | 27,321 | 27,355 | 34,054 | 35,860 | 50,040 |
| Announcement Date | 24/03/20 | 23/03/21 | 22/03/22 | 22/03/23 | 13/03/24 | 19/03/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 305M | |
| 34.3x | 12.25x | 25.74x | 0.59% | 1,030B | |
| 27.42x | 6.27x | 17.37x | 2.1% | 617B | |
| 32.4x | 7.6x | 15.6x | 2.67% | 455B | |
| 19.58x | 4.68x | 11.59x | 2.83% | 350B | |
| 22.31x | 5.76x | 14.38x | 2.78% | 299B | |
| 21.88x | 4.51x | 12.77x | 1.94% | 265B | |
| 14.62x | 5.41x | 11.16x | 3.43% | 225B | |
| 25.46x | 6.65x | 11.72x | 2.6% | 209B | |
| -47.31x | 5.67x | 31.32x | 2.51% | 163B | |
| Average | 16.74x | 6.53x | 16.85x | 2.38% | 361.3B | |
| Weighted average by Cap. | 24.14x | 7.76x | 18.30x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SCPH Stock
- Valuation scPharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
